Deprescribing Antipsychotics: a Multiple Case Study

NCT07343193 | Recruiting

• 1 other identifier: 9822
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The literature on antipsychotic deprescribing highlights the difficulty in establishing a clear consensus on the most optimal strategy due to the diversity of clinical situations encountered in daily practice: who should be deprescribed, when, at what rate, what strategy to employ in case of relapse, etc. The fear of relapse leads psychiatrists (particularly in France) to tend to maintain long-term treatment, even if the arguments for this maintenance may be debatable due to an uncertain benefit-risk balance. Conversely, patients often request a reduction or discontinuation, notably because of the side effects of the treatments. This argument serves to justify the value of presenting unique clinical situations like those in this study in a publication. The goal is for readers to gain a practical understanding of the successes and difficulties of deprescribing in real-life situations.

Conditions

Psychotic Disorder

Keywords

Psychotic Disorder; Psychotic or Related Disorder; Antipsychotics

Outcome Measures

Primary Outcomes (1)

• Describe clinical situations where discontinuation of antipsychotics or a reduction of antipsychotics below the theoretically minimum recommended doses was possible.

  Stopping or reducing treatment: * Some patients may do well with less medication, * or even without medication, under carefully monitored conditions.

  Up to 12 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults patients with a psychotic or related disorder

You may qualify if:

• Adults (≥18 years)
• Patients with a psychotic or related disorder
• Patients on long-term antipsychotic treatment, clinically stable, who accept or request a deprescription between January 1, 2021, and October 30, 2025

You may not qualify if:

• \- Patients who have expressed their opposition to participating in the study

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service de Psychiatrie 1 - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Psychotic Disorders; Mental Disorders

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders

Central Study Contacts

Fabrice BERNA, MD, PhD

CONTACT

33 3 88 11 64 62; fabrice.berna@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 6, 2026
• First Posted: January 15, 2026
• Study Start: September 9, 2025
• Primary Completion (Estimated): September 1, 2026
• Study Completion (Estimated): September 9, 2026
• Last Updated: January 15, 2026

Record last verified: 2026-01

Locations

FR (1)